Protocol Ledger

NCT05399368 · Phase II · TERMINATED

An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis

Interventional Phase II clinical trial protocol NCT05399368 sponsored by GSK in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-06-07 Enrollment: 229 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05399368
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)229 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05399368
Protocol FieldVerified Registry Value
NCT IdentifierNCT05399368
Consolidated Lead SponsorGSK
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment229 participants (ACTUAL)
Registered Start Date2022-06-07
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05399368
Hospital Research SiteLocationSite Profile
California Dermatology & Clinical Research InstituteEncinitas, CAOpen Hospital Dossier ->
First OC DermatologyFountain Valley, CAOpen Hospital Dossier ->
Dermatology Research AssociatesLos Angeles, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for GSK across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI